Gemida, Jocelyn A.
HRN: 25-18-58 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/12/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
06/12/2024
06/24/2024
IV
500mg
Q8H
Rectal Adenocarcinoma Stage 4
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes